PBYI Q3 2018 Earnings — Puma Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

PBYIPuma Biotechnology, Inc.

$299M

Q3 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$63M+930.1% YoY

Gross Profit

$54M85.6% margin

Operating Income

-$11M-18.1% margin

Net Income

-$14M-22.7% margin

EPS (Diluted)

$-0.37

QoQ Revenue Growth

+23.3%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$8M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$231M

Total Liabilities

$185M

Stockholders' Equity

$46M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$63M	$6M	+930.1%
Gross Profit	$54M	$5M	+1077.8%
Operating Income	-$11M	-$77M	+85.4%
Net Income	-$14M	-$77M	+81.6%

Revenue Segments

Product

$53M84%

License

$10M16%